Purpose of the study: Research dynamic of parameters of mineral metabolism, during 12 months therapy with Strontium ranelate (in dose 2 g/day) at women with postmenopausal osteoporosis and diabetes type 2 (D2).
Materials and methods: Forty-two women (age 65.9±3.2 years) in postmenopausal period with verified DM2 (DM2 longer from 1 to 12 years, all patients have standard on per oral therapy with ant diabetes drag gliclazide, metformin or rosiglitazone) and postmenopausal osteoporosis (DEXA T-score less −2.5).
Clinical results: 11.9% of patients have dyspeptic phenomena (regress was during 13 days. Nobody of the patients finish treatment in early stage of treatment). Bone mineral density at DEXA T-score grow on 21.5±2.86% (P=0.05), lumbar spine L 1 16.5%, L2 a 18.4%, L3 23%, femoral neck 24.87%, Wards 16.7%, Troch. 27.3%, Total hip 23.35% (P=0.05).
Calcium, and alkaline phosphates are in normal range, on background of therapy negative dynamic is not revealed. Serum C- telopeptide cross link before treatment raised at 33%. And after one year treatment with Strontium ranelate was note regress on 33.5% (r=0.05).: 88.1% of women had pain syndrome (in spine or in the hip), after 2 month of the therapy 2.4% mark its regress, 11.9% after 4 months, 23% after 6 months, 33% after one year treatment of Strontium ranelate. Nobody of the patient had hypoglycemia. Nobody have nonvertebral and vertebral fracture risks.
Conclusions: Strontium ranelate, being effective in reducing both nonvertebral and vertebral fracture risks. Strontium ranelate is a new first treatment of postmenopausal osteoporosis and diabetes type 2.
30 Apr - 04 May 2011
European Society of Endocrinology